Please login to the form below
empagliflozin
This page shows the latest empagliflozin news and features for those working in and with pharma, biotech and healthcare.
J&J’s Invokana aces diabetic kidney disease trial, setting up filings
risk of lower-limb amputation in diabetics, putting it at a disadvantage compared to rival SGLT2 drugs such as Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin) and AstraZeneca’s Farxiga
Latest news
-
J&J says real-world data finds no amputation risk for Invokana
s Jardiance (empagliflozin), but was also linked to an increased risk of lower-limb amputation.
-
Real-world data finds patients feel better on Entresto, says Novartis
s Jardiance (empagliflozin), as around a third of patients with heart failure also have diabetes.
-
FDA’s year-end approvals take annual tally to 46
established drugs Johnson &Johnson’s first-to-market blockbuster Invokana (canagliflozin) - which brought in more than $1.2bn last year - fast-gaining rival Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim
-
Lilly mulls divestment of its animal health operations
to surging sales of diabetes drugs Trulicity (dulaglutide) and Jardiance (empagliflozin) and a near five-fold increase for psoriasis drug Taltz (ixekizumab).
-
J&J seeks US OK to add CV claim to Invokana label
If the FDA approves the label, Invokana could be able to match rival SGLT2 inhibitor Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim, which had cardiovascular outcomes data added to its
More from news
Approximately 15 fully matching, plus 64 partially matching documents found.
Latest Intelligence
-
Market dynamics, marketing and analytics
The remaining two SGLT2s are growing faster than the market, with Jardiance (empagliflozin) leading the market in terms of growth.
-
Interview: Christopher Boulton, AstraZeneca
s empagliflozin, but AstraZeneca's strength is the wide range of oral diabetes products it has to offer, says Boulton. “
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Business Unit Head, Medical Communications, London
-
Excellent package
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- Roche keeps Venclexta train rolling with new leukaemia filing
- NHS England says yes to Roche's Hemlibra
- Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices
- Huntsworth buys Giant Creative Strategy
- Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
- Brexit rebels win vote on European Medicines Agency alignment
- Data Visualisation
- The True Potential of Mobile Health Tech
- NHS England to Vertex: come clean on Orkambi offer
PMHub
Quintiles Medical Communications
Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
